Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan
Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional ...
Rhythm Pharmaceuticals gets orphan drug designation for setmelanotide in Japan
Rhythm Pharmaceuticals (RYTM) announced it has received orphan drug designation from Japan’s Ministry of Health, Labour and Welfare for ...